Question 1

What are the potential side effects of Pembrolizumab and IO102-103?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). clinical trial (NCT05977907). Contact the study team or your healthcare provider for specific answers.

Question 2

How will this treatment affect my surgery schedule?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). clinical trial (NCT05977907). Contact the study team or your healthcare provider for specific answers.

Question 3

What tests or procedures will I need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). clinical trial (NCT05977907). Contact the study team or your healthcare provider for specific answers.

Question 4

Are there any risks associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). clinical trial (NCT05977907). Contact the study team or your healthcare provider for specific answers.

Question 5

How does this treatment compare to standard options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). clinical trial (NCT05977907). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). clinical trial (NCT05977907). Contact the study team or your healthcare provider for specific answers.

What this study is about